Qinde Yang1, Jing Wang2, Yufang Yang3, Suting Li4, Yujun Dong5, Yan Sun6. 1. Department of Laboratory, People's Hospital of Guangrao County Dongying, Shandong Province, China. 2. Department of Laboratory, Tianjin Fifth Central Hospital Tianjin City, China. 3. Department of Laboratory, The Second People's Hospital of Dongying Dongying, Shandong Province, China. 4. Department of Internal Medicine, Binzhou Polytechnic Binzhou, Shandong Province, China. 5. Department of Laboratory, Liaocheng Dongchangfu People's Hospital Liaocheng, Shandong Province, China. 6. Department of Pharmacy, The Second People's Hospital of Dongying Dongying, Shandong Province, China.
Abstract
OBJECTIVE: To evaluate the in vitro antibacterial effect of vancomycin hydrogel on methicillin-resistant Staphylococcus aureus (MRSA). METHODS: We used polylactide glycolide-polyethylene glycol-polylactide glycolide (PLGA-PEG-PLGA) copolymer as a carrier of vancomycin to prepare vancomycin hydrogel. A vancomycin hydrogel group, a PLGA-PEG-PLGA copolymer group, a phosphate-buffered saline (PBS) negative control group and a vancomycin group were set for comparison. Then, we analyzed the in vitro antibacterial effect of each group to determine the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) and to evaluate the effect of vancomycin hydrogel on the cell activity of bacterial biofilms. RESULTS: The temperature of the successfully prepared PLGA-PEG-PLGA vancomycin copolymer was slightly lower than normal body temperature. The copolymer reduced both MIC (1 μg/mL) and MBC (2 μg/mL) for MRSA by 1 time. Compared with phosphate buffered saline negative control group and PLGA-PEG-PLGA copolymer group, the MIC vancomycin and vancomycin hydrogel groups showed a reduction of 3 CFU/mL (P<0.05) on the inhibitory effect of original colony count (106 CFU/mL). Though the antibacterial effect of MIC the vancomycin group was significantly better than the vancomycin hydrogel group in the first 12 h, the antibacterial effects of the two were similar after 12 hours. The effect of 1 MIC vancomycin on the cell activity of MRSA biofilm was higher than that of 1 MIC vancomycin hydrogel (P<0.05). CONCLUSION: Vancomycin hydrogel with a reduced dosage has a similar antibacterial effect to vancomycin. This finding provides a reference for the development of novel sustained-release vancomycin formulations in future treatment of MRSA. AJTR
OBJECTIVE: To evaluate the in vitro antibacterial effect of vancomycin hydrogel on methicillin-resistant Staphylococcus aureus (MRSA). METHODS: We used polylactide glycolide-polyethylene glycol-polylactide glycolide (PLGA-PEG-PLGA) copolymer as a carrier of vancomycin to prepare vancomycin hydrogel. A vancomycin hydrogel group, a PLGA-PEG-PLGA copolymer group, a phosphate-buffered saline (PBS) negative control group and a vancomycin group were set for comparison. Then, we analyzed the in vitro antibacterial effect of each group to determine the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) and to evaluate the effect of vancomycin hydrogel on the cell activity of bacterial biofilms. RESULTS: The temperature of the successfully prepared PLGA-PEG-PLGA vancomycin copolymer was slightly lower than normal body temperature. The copolymer reduced both MIC (1 μg/mL) and MBC (2 μg/mL) for MRSA by 1 time. Compared with phosphate buffered saline negative control group and PLGA-PEG-PLGA copolymer group, the MIC vancomycin and vancomycin hydrogel groups showed a reduction of 3 CFU/mL (P<0.05) on the inhibitory effect of original colony count (106 CFU/mL). Though the antibacterial effect of MIC the vancomycin group was significantly better than the vancomycin hydrogel group in the first 12 h, the antibacterial effects of the two were similar after 12 hours. The effect of 1 MIC vancomycin on the cell activity of MRSA biofilm was higher than that of 1 MIC vancomycin hydrogel (P<0.05). CONCLUSION: Vancomycin hydrogel with a reduced dosage has a similar antibacterial effect to vancomycin. This finding provides a reference for the development of novel sustained-release vancomycin formulations in future treatment of MRSA. AJTR
Authors: Amany I Raafat; Naeem M El-Sawy; Nagwa A Badawy; Eglal A Mousa; Asmaa M Mohamed Journal: Int J Biol Macromol Date: 2018-07-12 Impact factor: 6.953